Clay Siegal Impact at Seattle Genetics

Many companies are working hard to develop new drugs that can manage various types of cancer. But Seattle Genetics is one of the companies that has invested heavily in research to produce high quality and effective drugs that can control cancer. Seattle Genetics was found in 1998, and Clay Siegal was one of the co-founders. Clay Siegal is highly educated. He joined the University of Maryland where he attained a degree in zoology. He later joined George Washington University where he achieved a PH.D. in genetics.

After graduating, he worked at National Institutes of Health, National Cancer Institute as well as Bristol-Myers Squibb Pharmaceutical Research Institute. After serving in this institutes, Clay decided co-founded Seattle Genetics with the aim of developing antibody-based cancer therapies. He helped the company in capital raising activities raising over $675 million through private and public finances in its early years. These funds are used to finance research and development of new drugs.

Seattle Genetics has been working hard to ensure they market their new products globally. The company specializes in the manufacture of Antibody-Drug Conjugate (ADC) which target antigens which stimulate the immune system to produce antibodies. These drugs attach themselves outside cancer cells and deposit toxins inside the cells that eventually kill them. This is a better approach as this approach reduces normal tissue damage evident in chemotherapy as well a radiation.

Siegal has been very influential in making sure the company develops many drugs that are helpful in cancer management. Currently, the company has 11 drugs in the pipeline and Siegal is confident that four of them will attract huge sales. The first drug is Adcertris which has been approved by the Food and Drug Administration as one of the drugs for Hodgkin lymphoma. This medication should be used if the first and second drugs don’t show the impact on the patient. Siegal predicts Adcetris will make sales of over $1 billion annually. If all the tests show dramatic impact, there is no doubt that this drug could be recommended as a first therapy.

The second drug is 33A. This drug targets AML (acute myeloid leukemia) which has been a challenge for decades. Seattle Genetics is working hard to release this drug so that it can manage this form of blood cancer. The other drugs include 22ME as well as LIV1 which target bladder cancer and breast cancer respectively. Clay Siegal has been very instrumental in Seattle Genetics operations, and he is confident the company will achieve its objectives in research as well as sales.